Open label study of alprazolam in severely depressed inpatients.
Severely depressed inpatients received alprazolam in doses adjustable from 1.5 mg to 5.0 mg/day. Half of the 26 patients improved with greater than or equal to 50% reduction on the Hamilton Psychiatric Rating Scale for Depression or had a final total score of 8 or less. Patient response to treatment over the 6-week study was associated with marked improvement during the first week.
D000293:Adolescent; D000328:Adult; D000525:Alprazolam; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D000525:Alprazolam